Friday, 13 November 2026European Markets

PROXIMUS And HIGH CO Have A High Dividend Yield And Return On Equity In The Communication Services Sector.

Loading stream...

(vianews) - proximus (prox.br) is among this list of stock assets with the highest dividend rate and return on equity on the communication services sector.

financial asset price forward dividend yield return on equity
proximus (prox.br) €7.88 17.24% 12.18%
high co (hco.pa) €4.82 9.11% 3.99%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. proximus (prox.br)

17.24% forward dividend yield and 12.18% return on equity

proximus plc provides digital services and communication solutions in belgium and internationally. it operates through domestic, international carrier services, and telesign segments. the company offers fixed and mobile telephony, internet, and television services to residential customers and small businesses, and ict services to residential, business, and telecom wholesale markets. it also provides managed and platform, integrating networking, cloud, cybersecurity, business application, and data and artificial intelligence services. in addition, the company offers international delivery authentication and digital identity services to internet brands, digital champions, and cloud native businesses. it offers its products and services under proximus, scarlet, mobile vikings, tango, telindus, and telindus netherlands brands. the company was formerly known as belgacom sa and changed its name to proximus plc in june 2015. proximus plc was founded in 1930 and is headquartered in brussels, belgium.

earnings per share

as for profitability, proximus has a trailing twelve months eps of €1.23.

pe ratio

proximus has a trailing twelve months price to earnings ratio of 6.41. meaning, the purchaser of the share is investing €6.41 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.18%.

revenue growth

year-on-year quarterly revenue growth grew by 3.8%, now sitting on 6b for the twelve trailing months.

yearly top and bottom value

proximus's stock is valued at €7.88 at 12:30 est, way below its 52-week high of €11.39 and way higher than its 52-week low of €6.39.

moving average

proximus's value is above its 50-day moving average of €7.40 and below its 200-day moving average of €7.89.

sales growth

proximus's sales growth for the next quarter is negative 0.2%.

more news about proximus.

2. high co (hco.pa)

9.11% forward dividend yield and 3.99% return on equity

high co. sa provides marketing solutions to various retailers and brands worldwide. the company offers brand platform, communication strategy, social media engagement, and media strategy services; and service design services, sms and push notifications, mobile applications and websites, and loyalty programs. it also provides data collection and analysis, targeting and personalization drivers, predictive algorithms, and gdpr compliant technologies; and promotion mechanics, multi-channel distribution, logistics and merchandising, and operational management and coupon processing services. the company was founded in 1990 and is headquartered in aix-en-provence, france.

earnings per share

as for profitability, high co has a trailing twelve months eps of €0.16.

pe ratio

high co has a trailing twelve months price to earnings ratio of 30.13. meaning, the purchaser of the share is investing €30.13 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.99%.

more news about high co.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com